CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017

Basel, Switzerland, Thursday, May 4, 2017 - CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma [...]

CIS Pharma’s solubilization technology comprising cyclosporine A has entered proof of concept phase

Bubendorf, Switzerland, Friday, October 21, 2016 - CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates [...]

CIS Pharma has successfully concluded the development of novel contact lens coating technology

Bubendorf, Switzerland, Monday, September 5, 2016 - CIS Pharma has concluded the development of a novel contact lens coating technology based on the Cellophil® Smart Polymer platform. The technology has [...]

CIS Pharma announces the first milestones in its ADC research program are achieved

Bubendorf, Switzerland, Thursday, January 21, 2016 - Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers [...]

CIS Pharma creates novel contact lens coating technology

Bubendorf, Switzerland, Tuesday, November 17, 2015 - CIS Pharma is expanding its Cellophil® Smart Polymer platform with new bio-inspired derivatives. The derivatives are used as building blocks for the development [...]

CIS Pharma develops solubilization technology for hydrophobic drugs

Bubendorf, Switzerland, Tuesday, September 2, 2015 - CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The [...]

CIS Pharma to develop drug carriers for ADCs

Bubendorf, Switzerland, Monday, January 12, 2015 - CIS Pharma has taken a strategic decision to extend its activity into the field of cancer treatments. The defined objective is to improve [...]